tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Arcutis Biotherapeutics (ARQT) with a Neutral rating and $18 price target The company’s lead asset Zoryve has a favorable profile and is preferred by many dermatologists over generic topicals and steroids, but its growth going forward may be challenged, the analyst tells investors in a research note. The firm awaits clarity on Zoryve before recommending Arcutis shares.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1